Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:Steven Hopkins; Faiz Baqai, Saivaroon Gajagowni, Gavin Hickey Abstract: Journal of Cardiovascular Pharmacology and Therapeutics, Volume 30, January-December 2025. BackgroundSodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated significant cardiovascular benefits in clinical trial. While their role in reducing heart failure hospitalizations and cardiovascular mortality is well established, the precise ... Citation: Journal of Cardiovascular Pharmacology and Therapeutics PubDate: 2025-04-13T03:10:42Z DOI: 10.1177/10742484251323428 Issue No:Vol. 30 (2025)
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Abstract: Journal of Cardiovascular Pharmacology and Therapeutics, Volume 30, Issue , January-December 2025.
Citation: Journal of Cardiovascular Pharmacology and Therapeutics PubDate: 2025-02-17T04:38:40Z DOI: 10.1177/10742484251315246 Issue No:Vol. 30 (2025)
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:Sarah K. Gharib, Abid M. Sadiq, Faryal M. Raza, Sophia S. Muhali, Annette A. Marandu, Norman J. Kyala, Eliasa K. Ndale, Venance P. Maro, William P. Howlett, Elifuraha W. Mkwizu, Nyasatu G. Chamba, Furaha S. Lyamuya, Elichilia R. Shao, Kajiru G. Kilonzo; Abid M. Sadiq, Faryal M. Raza, Sophia S. Muhali, Annette A. Marandu, Norman J. Kyala, Eliasa K. Ndale, Venance P. Maro, William P. Howlett, Elifuraha W. Mkwizu, Nyasatu G. Chamba, Furaha S. Lyamuya, Elichilia R. Shao, Kajiru G. Kilonzo Abstract: Journal of Cardiovascular Pharmacology and Therapeutics, Volume 30, Issue , January-December 2025. BackgroundVitamin K antagonists (VKA) continue to be the principal anticoagulants for both the treatment and prevention of venous thromboembolism. The use of VKA often requires regular monitoring to avoid over-anticoagulation and prevent thromboembolic complications. The aim was to determine the indication for VKA use and factors associated with suboptimal anticoagulation control among patients in northern Tanzania.MethodsThis was a retrospective cohort study that examined the anticoagulation data of patients on long-term VKA from 1st January 2020 to 31st December 2022. Eligible participants were those on VKAs for at least 7 days and with at least 3 international normalized ratio (INR) results. The level of anticoagulation control was determined through the calculation of the time-in-therapeutic range (TiTR) using the Rosendaal and the percent of INR in therapeutic range methods.ResultsTiTR was found to be 17% using the direct method and 16% using the Rosendaal formula. 102 tests out of 365 were within the target range (28%). Absence of health insurance (aRR: 1.24, 95% CI: 1.06-1.44, P = .007), alcohol consumption (aRR: 1.37, 95% CI: 1.15-1.62, P Citation: Journal of Cardiovascular Pharmacology and Therapeutics PubDate: 2025-01-22T09:30:08Z DOI: 10.1177/10742484251315104 Issue No:Vol. 30 (2025)
Please help us test our new pre-print finding feature by giving the pre-print link a rating. A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Authors:Tyler Shugg, Tk Nguyen, Xuesi Hua, Blair Richards, James Rae, Robert Dess, Daniel Perry, Bradley Kay, Salim S. Hayek, Monika Leja, Jasmine A. Luzum; Tk Nguyen, Xuesi Hua, Blair Richards, James Rae, Robert Dess, Daniel Perry, Bradley Kay, Salim S. Hayek, Monika Leja, Jasmine A. Luzum Abstract: Journal of Cardiovascular Pharmacology and Therapeutics, Volume 30, Issue , January-December 2025. BackgroundNeurohormonal blocking drugs, like beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs), are recommended for treating anthracycline-induced left ventricular dysfunction (AILVD). However, there is limited evidence supporting their benefit. Therefore, this study evaluated associations of neurohormonal blockers and other clinical factors with recovery of left ventricular ejection fraction (LVEF) in patients with AILVD.MethodsThis retrospective chart review assessed patients treated with at least one dose of anthracycline, then had ≥10% LVEF reduction or post-anthracycline LVEF value Citation: Journal of Cardiovascular Pharmacology and Therapeutics PubDate: 2025-01-13T07:50:21Z DOI: 10.1177/10742484241304304 Issue No:Vol. 30 (2025)
Hybrid journal (It can contain Open Access articles)
